AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 262.7 USD | -0.53% |
|
-2.71% | -8.80% |
| Apr. 17 | UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating | MT |
| Apr. 16 | Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease | MT |
Financials (USD)
| Sales 2024 * | 32.99B | Sales 2025 * | 34.15B | Capitalization | 141B |
|---|---|---|---|---|---|
| Net income 2024 * | 6.1B | Net income 2025 * | 7.56B | EV / Sales 2024 * | 5.68 x |
| Net Debt 2024 * | 46.47B | Net Debt 2025 * | 40.28B | EV / Sales 2025 * | 5.31 x |
| P/E ratio 2024 * |
22.9
x | P/E ratio 2025 * |
17.7
x | Employees | 26,700 |
| Yield 2024 * |
3.53% | Yield 2025 * |
3.82% | Free-Float | 99.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amgen Inc.
More recommendations
More press releases
More news
| 1 day | -0.53% | ||
| 1 week | -2.71% | ||
| Current month | -7.61% | ||
| 1 month | -3.03% | ||
| 3 months | -13.73% | ||
| 6 months | -7.37% | ||
| Current year | -8.80% |
1 week
262.58
270.93
1 month
262.58288.57
Current year
262.58329.72
1 year
211.71329.72
3 years
198.64329.72
5 years
166.30329.72
10 years
108.20329.72
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 06-05-31 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 19-10-22 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | Dec. 17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 17-02-02 |
Ellen Kullman
BRD | Director/Board Member | 68 | 16-10-13 |
Robert Williams
BRD | Director/Board Member | 75 | 14-10-16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 120 M€ | +8.74% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 262.8 | -0.50% | 2,082,791 |
| 24-04-17 | 264.1 | -0.59% | 2,175,120 |
| 24-04-16 | 265.6 | +0.05% | 2,017,573 |
| 24-04-15 | 265.5 | -0.66% | 1,740,174 |
| 24-04-12 | 267.3 | -1.01% | 2,140,134 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
262.8
USD
Average target price
300.3
USD
Spread / Average Target
+14.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.80% | 141B | |
| +27.97% | 672B | |
| +23.58% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.96% | 211B | |
| -0.41% | 203B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- AMGN Stock
